The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker

Oncologist

Volumn 16, Issue 9, 2011, Pages 1280-1291

  Papageorgiou, Sotirios G ^a   Kontos, Christos K ^a   Pappa, Vassiliki ^a   Thomadaki, Hellinida ^a   Kontsioti, Frida ^a   Dervenoulas, John ^a   Papageorgiou, Efstathios ^a   Economopoulos, Theofanis ^a   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

BCL2 family; Bcl2l12; Chronic lymphocytic leukemia; CLL; Real time PCR; Tumor biomarkers

Indexed keywords

BIOLOGICAL MARKER; CD38 ANTIGEN; COMPLEMENTARY DNA; MESSENGER RNA; PROPIDIUM IODIDE;

ADULT; AGED; APOPTOSIS; ARTICLE; BCL2L12 GENE; CANCER CELL; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GREEN CHEMISTRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUSCLE PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; SEQUENCE ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053196884     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0349     Document Type: Article

References (69)

1. Caligaris-Cappio F. Biology of chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000;4:5-21.
2. Abbott BL. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. The Oncologist 2006;11:21-30.
3. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.
4. Messmer BT, Messmer D, Allen S L et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005;115:755-764.
5. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003;123:380-388.
6. Munk Pedersen I, Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 2004;45:2365-2372.
7. Van Bockstaele F, Verhasselt B, Philippe J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev 2009;23:25-47.
8. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008; 371:1017-1029.
9. Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
10. Rai KR, Sawitsky A, Cronkite E P et al. Clinical staging of chronic lym-phocytic leukemia. Blood 1975;46:219-234.
11. Kalil N, Cheson BD. Chronic lymphocytic leukemia.The Oncologist 1999; 4:352-369.
12. Reed JC. Dysregulationof apoptosisincancer. J Clin Oncol 1999;17:2941-2953.
13. Krajewski S, Krajewska M, Turner B C et al. Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 1999;6:29-40.
14. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26: 239-257.
15. Sasi N, Hwang M, Jaboin J et al. Regulated cell death pathways: new twists in modulation of BCL2 family function. Mol Cancer Ther 2009;8:1421-1429.
16. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000;157:1415-1430.
17. Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 2004;1644:83-94.
18. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-1326.
19. Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 2006;43:1-67.
20. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008;27: 6398-6406.
21. Schena M, Gottardi D, Ghia P et al. The role of Bcl-2 in the pathogenesis of B chronic lymphocytic leukemia. Leuk Lymphoma 1993;11:173-179.
22. Faderl S, Keating MJ, Do K A et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002;16:1045-1052.
23. Kitada S, Andersen J, Akar S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998;91:3379-3389.
24. Robertson LE, Plunkett W, McConnell K et al. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996;10:456-459.
25. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999;17:399-408.
26. Scorilas A, Kyriakopoulou L, Yousef G M et al. Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. Genomics 2001;72:217-221.
27. Floros KV, Talieri M, Scorilas A. Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biol Chem 2006;387:1629-1633.
28. Floros KV, Thomadaki H, Florou D et al. Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide. Ann N Y Acad Sci 2006;1090:89-97.
29. Floros KV, Thomadaki H, Katsaros N et al. mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12,inHL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem 2004;385:1099-1103.
30. Floros KV, Thomadaki H, Lallas G et al. Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12. Ann N Y Acad Sci 2003;1010:153-158.
31. Thomadaki H, Floros KV, Scorilas A. Molecular responseof HL-60 cells to mitotic inhibitors vincristine and taxol visualized with apoptosis-related gene expressions, including the new member BCL2L12. Ann NY Acad Sci 2009;1171:276-283.
32. Mu QT, Ouyang GF, Lou Y R et al. [Inducing-apoptosis effect of bort-ezomib on acute monocytic leukemia cell SHI-1 and its influence on expressions of Bcl2l12, Bcl-2 and Bax genes]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008;16:1016-1020.
33. Hong Y, Yang J, Chi Y et al. BCL2L12A localizes to the cell nucleus and induces growth inhibition through G2/M arrest in CHO cells. Mol Cell Biochem 2010;333:323-330.
34. Hong Y, Yang J, Wu W et al. Knockdown of BCL2L12 leads to cisplatin resistance in MDA-MB-231 breast cancer cells. Biochim Biophys Acta 2008;1782:649-657.
35. Gattenloehner S, Chuvpilo S, Langebrake C et al. Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression. Blood 2007;110:2027-2033.
36. Cheson BD, Bennett JM, Grever M et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.
37. Hamblin TJ, Orchard JA, Ibbotson R E et al. CD38 expression and immu-noglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023-1029.
38. Koopman G, Reutelingsperger CP, Kuijten G A et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994;84:1415-1420.
39. Stavroyianni N, Belessi C, Stamatopoulos K et al. Expression of recombination activating genes-1 and-2 immunoglobulin heavy chain gene rearrangements in acute myeloid leukemia: evaluation of biological and clinical significance in a series of 76 uniformly treated patients and review of the literature. Haematologica 2003;88:268-274.
40. Ghia P, Stamatopoulos K, Belessi C et al. Geographic patterns and patho-genetic implications ofIGHV gene usage inchronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 2005;105:1678-1685.
41. Stamatopoulos K, Belessi C, Moreno C et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007;109:259-270.
42. Lefranc MP, Giudicelli V, Kaas Q et al. IMGT, the international ImMuno-GeneTics information system. Nucleic Acids Res 2005;33:D593-597.
43. Giulietti A, Overbergh L, Valckx D et al. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001;25:386-401.
44. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408.
45. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-7259.
46. Mathioudaki K, Scorilas A, Papadokostopoulou A et al. Expression analysis ofBCL2L12, anew member ofapoptosis-related genes, in colon cancer. Biol Chem 2004;385:779-783.
47. Kontos CK, Papadopoulos IN, Scorilas A. Quantitative expression analysis and prognostic significance of the novel apoptosis-related gene BCL2L12 in colon cancer. Biol Chem 2008;389:1467-1475.
48. Talieri M, Diamandis EP, Katsaros N et al. Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. Thromb Haemost 2003;89:1081-1088.
49. Thomadaki H, Talieri M, Scorilas A. Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Lett 2007;247: 48-55.
50. Florou D, Papadopoulos IN, Scorilas A. Molecular analysis and prognostic impact of the novel apoptotic gene BCL2L12 in gastric cancer. Biochem Biophys Res Commun 2010;391:214-218.
51. Stegh AH, Kim H, Bachoo R M et al. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 2007;21:98-111.
52. Stegh AH, Brennan C, Mahoney J A et al. Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev 2010;24:2194-2204.
53. Stegh AH, ChinL, Louis DN et al. What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator. Cell Cycle 2008;7:2833-2839.
54. Stegh AH, Depinho RA. Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma.Cell Cycle 2011;10:33-38.
55. Stegh AH, Kesari S, Mahoney J E et al. Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA 2008;105:10703-10708.
56. Reed J C. Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. Behring Inst Mitt 1996;(97):72-100.
57. Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios inchronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997;76:935-938.
58. Pepper C, Hoy T, Bentley P. Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance. Leuk Lymphoma 1998;28:355-361.
59. Hanada M, Delia D, Aiello A et al. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993;82: 1820-1828.
60. Cimmino A, Calin GA, Fabbri M et al. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102:13944-13949.
61. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-15529.
62. Vasilatou D, Papageorgiou S, Pappa V et al. The role ofmicroRNAs in normal and malignant hematopoiesis. Eur J Haematol 2010;84:1-16.
63. Binet JL, Caligaris-Cappio F, Catovsky D et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006;107:859-861.
64. Montserrat E. Treatment of chronic lymphocytic leukemia: achieving minimal residual disease-negative status as a goal. J Clin Oncol 2005;23:2884-2885.
65. Kröber A, Seiler T, Benner A et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-1416.
66. Maloum K, Davi F, Merle-Beral H et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood 2000;96:377-379.
67. Oscier DG, Gardiner AC, Mould S J et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177-1184.
68. Vasconcelos Y, Davi F, Levy V et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lym-phocytic leukemia. J Clin Oncol 2003;21:3928-3932.
69. Damle RN, Wasil T, Fais F et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.